Beam Therapeutics Inc Asset Resilience Ratio
Beam Therapeutics Inc asset resilience ratio. Beam Therapeutics Inc (BEAM) has an Asset Resilience Ratio of 67.31% as of June 2026. The Asset Resilience Ratio measures the percentage of a company's total assets that are held in liquid form (cash and short-term investments). This metric indicates how well-positioned the company is to handle unexpected financial challenges, economic downturns, or strategic opportunities without requiring external financing. Read Beam Therapeutics Inc balance sheet liabilities for a breakdown of total debt and financial obligations.
Liquid Assets
Total Assets
Resilience Assessment
Asset Resilience Ratio of Beam Therapeutics Inc (2019–2025)
Asset resilience ratio of Beam Therapeutics Inc from 2019 to 2025. This chart shows how Beam Therapeutics Inc's Asset Resilience Ratio has changed over time. See Beam Therapeutics Inc free cash flow ratio to measure how efficiently the company converts operating cash flow to free cash.
Liquid Assets Composition Over Time
This chart breaks down Beam Therapeutics Inc's liquid assets into cash & equivalents and short-term investments, showing how the composition has evolved over time. For the complete balance sheet picture, see Beam Therapeutics Inc total assets.
Current Liquid Assets Breakdown
| Component | Amount | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 0% |
| Short-term Investments | $933.10 Million | 67.31% |
| Total Liquid Assets | $933.10 Million | 67.31% |
Asset Resilience Insights
- Very High Liquidity: Beam Therapeutics Inc maintains exceptional liquid asset reserves at 67.31% of total assets.
- This level provides strong protection against economic uncertainties but may indicate potential for more aggressive growth investments.
- The company has significant short-term investments, indicating active treasury management.
Beam Therapeutics Inc Industry Peers by Asset Resilience Ratio
Compare Beam Therapeutics Inc's asset resilience ratio with other companies in the same industry.
| Company | Industry | Asset Resilience Ratio |
|---|---|---|
|
Biomarin Pharmaceutical Inc
NASDAQ:BMRN |
Biotechnology | 0.00% |
|
HLB Co. Ltd
KQ:028300 |
Biotechnology | 3.29% |
|
Tubize-Fin
BR:TUB |
Biotechnology | 2.50% |
|
Shanghai Medicilon Inc
SHG:688202 |
Biotechnology | 6.69% |
|
Blue Jet Healthcare Limited
NSE:BLUEJET |
Biotechnology | 13.81% |
|
Hangzhou Biotest Biotech Co Ltd
SHG:688767 |
Biotechnology | 0.56% |
|
Shouyao Holdings (Beijing) Co. Ltd. A
SHG:688197 |
Biotechnology | 79.76% |
|
Shenzhen Weiguang Biological Products Co Ltd
SHE:002880 |
Biotechnology | 5.52% |
Beam Therapeutics Inc Asset Resilience Ratio by Year (2019–2025)
Beam Therapeutics Inc asset resilience ratio by year from 2019 to 2025. The table below shows the annual Asset Resilience Ratio data for Beam Therapeutics Inc.
| Year | Asset Resilience Ratio (%) | Liquid Assets | Total Assets | Change |
|---|---|---|---|---|
| 2025-12-31 | 64.16% | $950.27 Million | $1.48 Billion | +12.63pp |
| 2024-12-31 | 51.53% | $568.77 Million | $1.10 Billion | -0.13pp |
| 2023-12-31 | 51.65% | $753.98 Million | $1.46 Billion | -11.35pp |
| 2022-12-31 | 63.01% | $845.37 Million | $1.34 Billion | +35.49pp |
| 2021-12-31 | 27.51% | $405.65 Million | $1.47 Billion | -2.93pp |
| 2020-12-31 | 30.44% | $137.50 Million | $451.68 Million | -4.55pp |
| 2019-12-31 | 35.00% | $54.63 Million | $156.10 Million | -- |
About Beam Therapeutics Inc
Beam Therapeutics Inc., a biotechnology company, engages in the development of precision genetic medicines for patients suffering from serious diseases in the United States. Its programs in hematology and genetic disease portfolio include Ristoglogene autogetemcel, a patient-specific, autologous hematopoietic stem cell (HSC) therapy for the treatment of sickle cell disease; BEAM-302, a liver-targ… Read more